GSK5733584 / GSK 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GSK5733584 / GSK
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Recruiting
2
460
RoW
HS-20089
Hansoh BioMedical R&D Company
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
12/25
12/27
HS-20089-101, NCT05263479: A Study of HS-20089 in Patients With Advanced Solid Tumors

Recruiting
1
177
RoW
HS-20089 (Phase Iaļ¼šDose escalation ), HS-20089 (Phase Ib: Dose expansion)
Shanghai Hansoh Biomedical Co., Ltd
Advanced Solid Tumor
12/24
12/26
NCT06336707: HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Not yet recruiting
1
1048
NA
HS-20089, Adebrelimab, Bevacizumab, Cisplatin / carboplatin
Hansoh BioMedical R&D Company
Advanced Solid Tumors
04/26
04/28
NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Not yet recruiting
1
240
Europe, Canada, US, RoW
GSK5733584
GlaxoSmithKline
Solid Tumors
10/26
01/27

Download Options